161 related articles for article (PubMed ID: 38069135)
1. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria.
Gyoten M; Luo Y; Fujiwara-Tani R; Mori S; Ogata R; Kishi S; Kuniyasu H
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069135
[TBL] [Abstract][Full Text] [Related]
2. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
3. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt.
Park EK; Lee EJ; Lee SH; Koo KH; Sung JY; Hwang EH; Park JH; Kim CW; Jeong KC; Park BK; Kim YN
Br J Pharmacol; 2010 Jul; 160(5):1212-23. PubMed ID: 20590613
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.
Liu Y; Chen L; Gong Z; Shen L; Kao C; Hock JM; Sun L; Li X
Oncotarget; 2015 Feb; 6(5):3055-70. PubMed ID: 25605010
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents.
Li YC; Park MJ; Ye SK; Kim CW; Kim YN
Am J Pathol; 2006 Apr; 168(4):1107-18; quiz 1404-5. PubMed ID: 16565487
[TBL] [Abstract][Full Text] [Related]
7. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity.
Gupta VK; Sharma NS; Kesh K; Dauer P; Nomura A; Giri B; Dudeja V; Banerjee S; Bhattacharya S; Saluja A; Banerjee S
Cancer Lett; 2018 Dec; 439():101-112. PubMed ID: 30290209
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
10. Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines.
Masuo H; Kubota K; Shimizu A; Notake T; Miyazaki S; Yoshizawa T; Sakai H; Hayashi H; Soejima Y
Cancer Sci; 2023 Nov; 114(11):4388-4400. PubMed ID: 37700464
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway.
Liu DL; Bu HQ; Jin HM; Zhao JF; Li Y; Huang H
Mol Med Rep; 2014 Dec; 10(6):3027-34. PubMed ID: 25242370
[TBL] [Abstract][Full Text] [Related]
12. Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins.
Herrero-Martin G; López-Rivas A
FEBS Lett; 2008 Jul; 582(17):2589-94. PubMed ID: 18582466
[TBL] [Abstract][Full Text] [Related]
13. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
15. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
[TBL] [Abstract][Full Text] [Related]
16. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
17. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
Schniewind B; Christgen M; Kurdow R; Haye S; Kremer B; Kalthoff H; Ungefroren H
Int J Cancer; 2004 Mar; 109(2):182-8. PubMed ID: 14750167
[TBL] [Abstract][Full Text] [Related]
18. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
[TBL] [Abstract][Full Text] [Related]
19. Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis.
Xie J; Cheng CS; Zhu XY; Shen YH; Song LB; Chen H; Chen Z; Liu LM; Meng ZQ
Aging (Albany NY); 2019 May; 11(9):2681-2698. PubMed ID: 31076559
[TBL] [Abstract][Full Text] [Related]
20. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
